TrialReader


Fetal Treatment of Galenic Malformations

NCT04434729 — Not applicable, Completed, 7 participants, Darren Orbach

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04434729
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment7 (Actual)
SponsorDarren Orbach (Other)
ConditionsVein of Galen Malformations
InterventionsFetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils (Device)
Datesstart 2022-09-30, primary completion 2024-09-06, completion 2026-09-21, first posted 2020-06-17, last updated 2026-10-21
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Vein of Galen Malformations All trials of Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils

-Summary

This is a prospective, single-arm non-randomized interventional study of fetuses to assess the safety and efficacy of fetal embolization of Vein of Galen Malformation (VOGM). Subjects will receive a one-time study intervention of fetal embolization. Follow-up assessments will be collected every 4 weeks until delivery, as per standard of care. After delivery, neurological assessments will be performed every 6 months for 2 years (adjusted for gestational age). Data will be compared to historical cohorts.

Expand all sections  ·  Collapse all

+Detailed description

The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix. This procedure will take place in an obstetric OR at Brigham and Women's Hospital. Data will be collected every 4 weeks post-procedure until delivery, as per standard of care. Data regarding delivery and post-delivery status will also be collected until the subject is discharged from the hospital. After delivery, neurological assessments will be performed every 6 months for 2 years (adjusted for gestational age). Data will be compared to historical cohorts.

+Arms and interventions

ArmTypeInterventionsDescription
Fetal embolization of vein of Galen malformationExperimentalDevice: Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable CoilsThis is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
  • Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils (Device): The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.

+Outcome measures

Primary outcomes

  • Prenatal Safety of Fetal Embolization for Patients With Vein of Galen Malformations [From fetal embolization to delivery]: The procedure is deemed safe if 1. None of the following unacceptable events occur within 7 days of fetal embolization: 1. Fetal death 2. Fetal intracranial hemorrhage, either parenchymal or extra-axial, other than petechial hemorrhage. 3. Maternal death 2. None of the following unacceptable events occur between fetal embolization and delivery: 1. Intra-procedural and post-procedural morbidity to the fetus and mother, probably related to the fetal intervention, e.g. placental abruption with subsequent sequelae 2. Preterm delivery < 28 weeks, probably related to the fetal intervention 3. Maternal blood transfusion or unanticipated surgical intervention, probably related to the fetal intervention 4. Presence of fetal imaging evidence of new brain injury in a location or pattern unexpected for the natural history of vein of Galen malformation, probably related to the fetal intervention

Secondary outcomes

  • Efficacy of Fetal Embolization for Patients With Vein of Galen Malformations [Within 30 days of birth]: The procedure is deemed efficacious if none of the following serious postnatal events occur within 30 days of birth: 1. Urgent neonatal embolization is needed. Without fetal intervention, we'd expect 80% of the cohort to require such intervention. 2. Neonatal death. Without fetal intervention, we'd expect a mortality rate of 40% in this cohort. 3. Brain MRI within the first three weeks after birth reveals parenchymal brain injury (acute infarct or gliosis) affecting > 10% of the supratentorial brain volume. Without fetal intervention, we'd expect 30% of patients in this cohort to show this kind of injury.

+Eligibility

Sex: Female, ages: 18 Years to any

Inclusion Criteria:

* Pregnant woman carrying a fetus harboring a vein of Galen malformation in whom the straight sinus or falcine sinus draining the prosencephalic varix measures 7 mm or more on fetal MRI (medio-lateral diameter measured at the narrowest point of the sinus along the rostral-caudal axis, assessed on a T2-weighted coronal slice).
* Fetal gestational age between 23 weeks and term as determined by clinical information and evaluation of first ultrasound.
* Anatomic diagnosis of fetal vein of Galen malformation.
* Well preserved brain parenchyma.
* Maternal age of 18 years and older.
* Eligible for continuous lumbar epidural anesthesia.
* Able to travel to study site for study evaluation, procedures and visits.

Exclusion Criteria:

* Extensive fetal brain parenchymal injury/gliosis, >10% of supratentorial brain volume (i.e., SFP presentation). This is a degree of fetal brain injury beyond which the risk of significant neurological morbidity is high, based on studies of prenatal ischemic stroke.
* Irreversible fetal non-brain organ injury (e.g. hydrops fetalis as a manifestation of heart failure, a finding which portends fatal outcome in fetuses with vein of Galen malformation), i.e., SFP presentation.
* Fetus with VOGM in whom the straight sinus or falcine sinus draining the prosencephalic varix measures less than 7 mm on fetal MRI (T2-weighted coronal slice, medio-lateral diameter measured at the narrowest point of the sinus along the anterior-posterior axis), fitting fetal MRI criteria for likely evolution into the IT cohort.
* Severe maternal obesity pre-pregnancy as defined by body mass index (BMI) of 40 or greater.
* Fetuses with major congenital anomalies.
* Evidence of preterm labor, rupture of membranes or abruption.
* Maternal coagulopathy: INR > 1.2; PT/PTT above normal ranges for the lab; platelets <100.
* Medical disease requiring current anticoagulation including maternal deep vein thrombosis.
* Prior maternal medical history that would preclude epidural anesthesia.
* Multi-fetal pregnancy.
* Placenta previa or accreta.
* Participation in another fetal study that influences maternal and fetal morbidity and mortality.
* Known maternal hypersensitivity to 316LM stainless steel.
* Supine hypotensive syndrome.

+Posted results

Participant flow

MilestoneFetal Embolization of Vein of Galen Malformation
Started7
Completed5
Not completed2

Outcome results

  • Prenatal Safety of Fetal Embolization for Patients With Vein of Galen Malformations (Primary), Count of participants, Participants: Fetal Embolization of Vein of Galen Malformation 5
  • Efficacy of Fetal Embolization for Patients With Vein of Galen Malformations (Secondary), Count of participants, Participants: Fetal Embolization of Vein of Galen Malformation 2

Adverse events

Time frame: Adverse events were collected from the time of enrollment through 2 years post-delivery.

ArmDeathsSerious adverse eventsOther adverse events
Fetal Embolization of Vein of Galen Malformation3/7 (42.9%)2/7 (28.6%)2/7 (28.6%)

Serious adverse events by term

TermOrgan systemFetal Embolization of Vein of Galen Malformation
Sinus tachycardia, hypotensionCardiac disorders1/7
Complete chorion-amnion separationPregnancy, puerperium and perinatal conditions1/7

Other adverse events by term

TermOrgan systemFetal Embolization of Vein of Galen Malformation
Premature rupture of membranesPregnancy, puerperium and perinatal conditions1/7
Preterm premature rupture of membranes (PPROM)Pregnancy, puerperium and perinatal conditions1/7

+Locations (1)

FacilityCityCountryStatus
Boston Children's HospitalBoston, MassachusettsUnited States

+Publications

  • Results publication: Orbach DB, Shamshirsaz AA, Wilkins-Haug L, Guseh S, Krispin E, Tworetzky W, O'Leary B, Larson AM, Rangwala SD, Oushy S, See AP. In Utero Embolization for Fetal Vein of Galen Malformation. JAMA. 2025 Sep 9;334(10):878-885. doi: 10.1001/jama.2025.12363. PMID 40788723
  • Results publication: Orbach DB, Wilkins-Haug LE, Benson CB, Tworetzky W, Rangwala SD, Guseh SH, Gately NK, Stout JN, Mizrahi-Arnaud A, See AP. Transuterine Ultrasound-Guided Fetal Embolization of Vein of Galen Malformation, Eliminating Postnatal Pathophysiology. Stroke. 2023 Jun;54(6):e231-e232. doi: 10.1161/STROKEAHA.123.043421. Epub 2023 May 4. No abstract available. PMID 37139817
  • Results publication: See AP, Wilkins-Haug LE, Benson CB, Tworetzky W, Orbach DB. Percutaneous transuterine fetal cerebral embolisation to treat vein of Galen malformations at risk of urgent neonatal decompensation: study protocol for a clinical trial of safety and feasibility. BMJ Open. 2022 May 24;12(5):e058147. doi: 10.1136/bmjopen-2021-058147. PMID 35613814

+Study documents

+Investigators

My Notes